Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2024-03-29 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed financial data for the year 2023, including main accounting data, financial indicators, quarterly data, shareholder information, and business descriptions. The document is over 8,000 characters, indicating it is a substantive report rather than a brief announcement. It includes comprehensive financial and operational information typical of an Annual Report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-03-29 Chinese
华兰生物工程股份有限公司章程
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 华兰生物工程股份有限公司 (Hualan Biological Engineering, Inc.). It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. The content is focused on the company's internal rules and governance framework rather than financial performance, audit results, or announcements. There is no indication that this is an annual report, earnings release, or any other financial or regulatory filing. The document is a governance document that sets out the company's constitution and rules for operation, which fits the definition of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, consistent with a CGR filing rather than a brief announcement or other category.
2024-03-29 Chinese
《董事会提名委员会议事规则》
Governance Information Classification · 95% confidence The document is titled '董事会提名委员会工作细则' which translates to 'Board Nomination Committee Working Rules'. It details the structure, responsibilities, meeting procedures, and governance related to the board nomination committee. There is no financial data, no mention of fiscal periods, no audit or financial results, and no indication of a report or announcement of financial performance. The content focuses on governance practices and internal rules related to board nominations and committee operations. This aligns with the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3657 characters, which is sufficient for a detailed governance document rather than a brief announcement. Therefore, the appropriate classification is CGR with high confidence.
2024-03-29 Chinese
关于续聘2024年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the auditing firm for the fiscal year 2024. It details the auditor's qualifications, independence, audit fees, and the approval process by the board and audit committee. It does not contain any financial statements or audit results but is a formal notice about the auditor appointment to be approved by the shareholders. The document length is short (2510 characters) and it is clearly an announcement rather than the audit report itself. Therefore, it fits best under the category of Audit Report / Information (AR) as it relates to audit matters but is not a full audit report or annual report. FY 2024
2024-03-29 Chinese
公司未来三年（2024-2026年）股东回报规划
Notice of Dividend Amount Classification · 95% confidence The document is a detailed plan outlining the company's shareholder return strategy for the years 2024-2026, including dividend distribution policies, timing, and decision-making processes. It references relevant laws and regulations and describes the company's approach to profit distribution and shareholder communication. It is not a financial report, earnings release, or regulatory filing but a formal announcement of a dividend policy plan. This fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend planning and shareholder returns over a multi-year period.
2024-03-29 Chinese
2023年监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2023 年度监事会工作报告' which translates to '2023 Supervisory Board Work Report'. It details the supervisory board's activities, meetings, oversight of company operations, financial condition, internal controls, and plans for 2024. It is a report from the supervisory board rather than a full annual report or audit report. It does not contain full financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not an announcement or a certification but a management-related report on oversight activities. Therefore, it fits best under Management Reports (MDA), which cover management's detailed explanation of business trends, financial results, and outlook, including supervisory board reports.
2024-03-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.